- Home
- MOVE vs KALV Comparison
MOVE vs KALV Comparison
Compare MOVE & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOVE | KALV |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 901.4M | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MOVE | KALV |
|---|---|---|
| Price | $16.28 | $19.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 103.1K | ★ 1.2M |
| Earning Date | 04-08-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $433,000.00 | ★ $50,000,000.00 |
| Revenue This Year | $1,460.71 | $185.42 |
| Revenue Next Year | $96.77 | $59.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $0.51 | $9.83 |
| 52 Week High | $34.87 | $21.31 |
Technical Indicators
Market Signals| Indicator | MOVE | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 50.66 |
| Support Level | $6.27 | $14.66 |
| Resistance Level | $20.62 | $21.31 |
| Average True Range (ATR) | 1.90 | 1.11 |
| MACD | 0.44 | -0.19 |
| Stochastic Oscillator | 90.77 | 6.36 |
Price Performance
Historical ComparisonAbout MOVE Movano Inc.
Corvex Inc is an AI cloud computing company specializing in GPU accelerated infrastructure for AI workloads. The company provides AI-focused computing infrastructure that offers scalable computational resources. Its platform uses GPU-accelerated compute clusters and high-throughput storage to support performance, security, and efficiency at scale. The company's product portfolio includes GPU Clusters, Inference-as-a-Service, Confidential Computing, and GPU Node.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.